Moderna (MRNA) Cash from Financing Activities (2018 - 2026)

Moderna (MRNA) has 9 years of Cash from Financing Activities data on file, last reported at $17.0 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $17.0 million, up 325.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $606.0 million (up 1217.39% YoY), and the FY2025 annual result was $593.0 million, up 958.93% from the prior year.
• Cash from Financing Activities declined to $17.0 million in Q1 2026 per MRNA's latest filing, from $581.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $581.0 million in Q4 2025 and troughed at -$1.3 billion in Q2 2022.
• A 5-year average of -$244.6 million and a median of -$3.0 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities plunged 51950.0% in 2022, then soared 19466.67% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$438.0 million in 2022, then soared by 75.11% to -$109.0 million in 2023, then jumped by 97.25% to -$3.0 million in 2024, then soared by 19466.67% to $581.0 million in 2025, then slumped by 97.07% to $17.0 million in 2026.
• Business Quant data shows MRNA's Cash from Financing Activities at $17.0 million in Q1 2026, $581.0 million in Q4 2025, and -$1.0 million in Q3 2025.